2nd ESTRO Forum 2013 modalities and strongly suggest durability of our results. Further follow up is needed to confirm this.
Purpose/Objective: International Prostate Symptoms Score (IPSS) at baseline and at one year follow-up were compared in Active Surveillance (AS) vs radical radiation (RT) pts. Aim of the present analysis was to determine if the expected changes in IPSS after RT has also psychological distress or age-related components in addition to radio-induced bladder/urethral toxicity. Materials and Methods: Between Dec 09 and Jul 12, 211 RT pts completed IPSS at baseline (T0) and 86/211 at one year from RT end (T1). Between Nov 07 and Nov 12, 145 AS pts completed the IPSS questionnaire at T0 and 57/145 at one year from AS enrolment (T1). IPSS was divided into 5 groups: =0 (no symptoms, symp), 1-7 (mild symp), 8-14 (mild to moderate symp), 15-19 (moderate symp) and 20-35 (severe symp). Possible associations between clinical variables and IPSS were determined through Pearson correlation coefficient. Clinically significant changes over time were defined as at least 4, 6, 8 IPSS increase, defined as mild, moderate and severe worsening, respectively. Z-test for proportions was used to investigate statistically significant differences in % of pts with mild to severe GU symp worsening in the two cohorts (AS vs RT). Results: Mean age: 65 vs 70 in AS and RT. Mean initial PSA: 5.1 vs 12.8 ng/ml, AS vs RT. AS pts were all ≤low-risk; RT pts: 26% low, 41.5% intermediate and 32.5% high-risk. Figure 1 shows the distribution of IPSS classes at T0 stratified by age and cohort. Youngest RT pts reported the best IPSS, while AS pts >70yrs showed the highest rate (24%) of moderate/severe symp. No significant correlation was found for age, clinical stage, initial PSA and BMI. 35% vs 21% pts (in AS and RT respectively, p=0.06) reported at least 4-point IPSS worsening, 24% vs 15% (p=0.16) and 12% vs 9% (p=0.58) at least 6 and 8-point increase, respectively. AS pts with IPSS at 2 yr follow-up (T2) showed that 86% of pts with 4-point worsening at T1 completely recovered to T0 level (90% and 83% for 6 and 8point).
Conclusions:
Our prostate cancer RT population reported less GU symp (as measured by IPSS) at T0 with respect to the AS population. % of pts with mild to severe GU symp worsening after 1 yr follow-up was higher in AS, but differences were not statistically significant. It has to be underlined that T1 AS IPSS measurement was performed one month after prostate re-biopsy (as established by AS protocol) and worsening of GU symp can be caused by biopsy-related acute toxicity. This hypothesis is confirmed if AS IPSS at 2 yrs is considered: 85-90% of pts recovered to T0 IPSS level. With respect to RT IPSS scores, the use of neo-adjuvant hormone therapy (40% of pts) could explain both T0 and T1 better IPSS in this cohort. Psychological distress or age-related components do not seem to play a significant role in GU function worsening at 1 yr in RT cohort. Longer follow-up is needed to determine the true impact of these variables on late GU radio-induced changes. (1, 2) . The aims of this trial are: (1) to evaluate the safety of applying this treatment strategy to patients receiving RT for high risk prostate cancer; (2) to establish the biochemical progression free survival in patients treated with hypoxia modification and (3) to study the changes in the tumour micro-environment using multi-parametric magnetic resonance (MR) imaging at different time points during the
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